They can prolong the survival of patients with SCLC in combination with the standard first-line chemotherapy to some extent.4 5 In IMPOWER-133, clinical survival was longer in patients receiving etoposide/carboplatin/atezolizumab than the control group.4 The phase 3 CASPIAN study in SCLC showed longer overall survival (OS) when adding PD-L1 inhibitors to chemotherapy.5 However, compared with patients with NSCLC, patients with SCLC did not get great benefit from immune-checkpoint inhibitors. Here, CD274 is linked to small cell lung carcinoma.